

Tuberculosis profile: Nigeria

Population 2019: 201 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	440 000 (287 000-625 000)	219 (143-311)
HIV-positive TB incidence	46 000 (30 000-66 000)	23 (15-33)
MDR/RR-TB incidence**	21 000 (13 000-32 000)	11 (6.3-16)
HIV-negative TB mortality	127 000 (74 000-195 000)	63 (37-97)
HIV-positive TB mortality	27 000 (17 000-40 000)	14 (8.5-20)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	4.3% (3.2-5.5)
Previously treated cases	14% (10-19)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	27% (19-41)
TB patients facing catastrophic total costs, 2017	71% (68-73)
TB case fatality ratio (estimated mortality/estimated incidence), 2019	37% (18-57)

TB case notifications, 2019

Total new and relapse	117 320
- % tested with rapid diagnostics at time of diagnosis	57%
- % with known HIV status	97%
- % pulmonary	96%
- % bacteriologically confirmed ^	75%
- % children aged 0-14 years	8%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	35%
- % men	57%
Total cases notified	120 266

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	12 052	11%
- on antiretroviral therapy	10 975	91%


Drug-resistant TB care, 2019

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	79%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	2 384
Patients started on treatment - MDR/RR-TB ^^^	1 975
Laboratory-confirmed cases - XDR-TB ^^	16
Patients started on treatment - XDR-TB ^^^	15
MDR/RR-TB cases tested for resistance to any fluoroquinolone	2 181


Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2018	87%	103 921
Previously treated cases, excluding relapse, registered in 2018	89%	2 612
HIV-positive TB cases registered in 2018	76%	12 700
MDR/RR-TB cases started on second-line treatment in 2017	77%	1 786
XDR-TB cases started on second-line treatment in 2017		


TB preventive treatment, 2019



Treatment success rate



Total budget



% of HIV-positive people (newly enrolled in care) on preventive treatment	73%
---	-----

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	16% (15-18)
---	----------------

TB financing

National TB budget, 2020 (US\$ millions)	384
--	-----

- Funding source, domestic	7%
----------------------------	----

- Funding source, international	23%
---------------------------------	-----

- unfunded	70%
------------	-----

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)